查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1715670

心臟衰竭POC 和 LOC 设备市场（按测试类型、设备类型、技术和最终用户划分）—2025 年至 2030 年全球预测

Heart Failure POC & LOC Devices Market by Test Type, Device Type, Technology, End User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

心臟衰竭POC 和 LOC 设备市场预计在 2024 年达到 2.6711 亿美元，2025 年达到 3.0192 亿美元，到 2030 年达到 5.6618 亿美元，复合年增长率为 13.33%。

主要市场统计数据
基准年2024年 2.6711亿美元
预计2025年 3.0192亿美元
预测年份 2030 5.6618亿美元
复合年增长率（%） 13.33%

在当今快速变化的医疗保健环境中，心臟衰竭即时诊断（POC）和实验室晶片（LOC）设备领域正在经历关键性的变革时期。由于技术创新和临床需求的增加，市场动态正在迅速变化。本执行摘要提供了有关新兴趋势、分类见解和竞争基准化分析的详细见解，以帮助相关人员了解市场成长的方向。先进的诊断技术与简化的患者管理方法的结合正在重塑传统模式。随着创新测试平台、复杂设备架构和以用户为中心的设计的引入，市场环境正在弥合紧急医疗和诊断准确性之间的差距。

该领域的发展受到重要技术突破和患者人口结构变化的影响。这些设备的重要性在于它们能够提供及时且准确的诊断，这对于减少心臟衰竭相关事件至关重要。在快速决策是临床黄金标准的时代，心臟衰竭POC 和 LOC 设备代表着卓越的工程技术和敏锐的医学洞察力的结合。随着高性能诊断工具的采用者转向提供更高可靠性和易用性的解决方案，整个行业的发展轨迹表明，未来即时数据将比以往任何时候都更能指导治疗途径。

本摘要旨在为希望利用这些不断发展的平台的潜力的决策者概述基本要素，包括市场区隔、区域影响、策略见解和可行的建议。本摘要提供了清晰的叙述，不仅回顾了当前的情况，而且预测了未来，重新定义了心臟衰竭的早期诊断和持续管理。

此外，它还强调了不断变化的法规、提高病患安全性以及与数位生态系统的整合等潜在因素。每个要素都在为广泛的市场采用奠定基础方面发挥关键作用。本书以经验证据和全面的市场研究为基础，为经验丰富的专业人士和行业新手提供了清晰的成功蓝图。

心臟衰竭诊断的前景正在发生巨大变化

近年来，在创新技术和动态市场需求的推动下，心臟衰竭诊断领域发生了重大变化。显着的变化来自于集体转向快速、分散、以患者为中心的诊断解决方案。科技的进步不仅简化了工作流程，而且重新定义了传统医疗保健基础设施的作用，以促进早期发现和持续监测。对即时数据和即时决策的重视正在形成一种新的说法，及时发现心臟异常可以显着改善患者的预后。

医疗保健提供者现在越来越多地整合先进的诊断工具，将实验室级分析带到护理点环境。这种转变是由对准确性、速度和易用性的强烈需求所驱动的。从繁琐的实验室程序到紧凑高效的 LOC 设备的转变改变了游戏规则。小型化平台和诊断过程数位化等进步已经使心臟衰竭管理得到发展，不仅支持临床结果，而且还支持医疗保健点的业务效率。

此外，技术的快速进步使得整合多种测试模式的诊断平台成为可能。这些技术的融合为涵盖全面的生物标记分析、即时监测和高效的数据管理等患者照护的整体方法铺平了道路。行业领导者现在专注于建立扩充性、互通性且临床稳健的系统。现代感测器技术融入数位健康平台正在激发创新，预计在不久的将来将彻底改变疾病管理通讯协定。

竞争解决方案越来越多地围绕着患者赋权的理念，即在传统临床环境之外进行诊断。医疗保健的民主化根源在于朝向便携式、易于使用的设备的转变，这些设备有助于对慢性病进行持续护理。将生物特征数据和可操作见解整合到穿戴式装置中是市场领导者采取的变革方法的一个例子。因此，这些转变不仅重塑了医疗服务的方式，也重新定义了心臟衰竭诊断领域的市场边界和投资机会。

心臟衰竭POC 和 LOC 设备的关键细分洞察

全面了解市场细分对于解读心臟衰竭POC 和 LOC 设备的细微差别至关重要。分割在客製化诊断以满足特定临床需求方面起着关键作用。細項分析方法表明，市场是根据测试类型、设备类型、技术和最终用户进行分類的。每个细分标准都包含不同的类别，从而指南我们的市场策略和发展工作。

根据测试类型，市场分为基因组测试、代谢组学测试和蛋白质组学测试。每种测试类型都为了解心臟衰竭的分子基础提供了独特的观点，为临床医生提供了早期诊断和有效管理策略的强大依据。基因组检测可以识别遗传风险因素，而代谢组学检测可以深入了解患者健康的生化过程。另一方面，蛋白质体学检测提供了有关蛋白质动力学及其与心臟功能的关係的精确资讯。

设备类型进一步细分为诊断设备和穿戴式装置。诊断设备包括心臟生物标记分析仪、心臟影像影像设备和心电图 (ECG) 系统，为床边带来高精度实验室功能。这些设备旨在提供快速、准确的数据，以促进在急性情况下快速做出临床决策。穿戴式设备，包括体外心臟去颤器和心率监测器，代表着向医院外持续、即时病患监测的转变。这些设备在非侵入性诊断中的作用是对在受控环境中进行的更复杂评估的补充。

在技​​术方面，基于生物感测器的系统、基于成像和电阻的平台、免疫测量和基于核酸的平台正在受到关注。这些创新确保了有效诊断心臟衰竭所必需的敏感性和特异性水平。这些创新利用先进的材料和微流体，提供快速的讯号处理，并与数位医疗记录无缝整合以增强数据分析。

最后，按最终用户细分涵盖各种临床环境，从辅助生活和居家照护设施到医院、诊所和专科实验室。这种广泛的频谱说明了市场上的产品正在多样化，以满足不同护理环境的不同操作要求和技术能力。这些设备能够灵活地适应不同的最终用户环境，这将增加它们的相关性并推动市场渗透。

每个细分层不仅定义了这些设备的技术和功能参数，而且还使开发优先顺序与患者和医疗保健专业人员的当前需求保持一致。了解这些关键的细分见解将有助于阐明推动心臟衰竭诊断解决方案创新和部署的机制。

目录

第一章 引言

第二章调查方法

第三章执行摘要

第四章 市场概述

第五章 市场洞察

  • 市场动态
    • 驱动程式
      • 心臟衰竭的盛行率和发病率在世界各地不断增加，需要及时的诊断和管理设备。
      • 对用于心臟生物标记分析的经济实惠且易于使用的 LOC 设备的需求日益增长
    • 限制因素
      • 心臟衰竭POC和LOC设备产品回想问题日益凸显
    • 机会
      • 将数位健康平台和远端医疗解决方案整合到 POC 和 LOC 设备中，以实现远端患者监护
      • 加强科技公司与医疗保健提供者之间的合作，开发心臟衰竭POC 和 LOC 设备
    • 任务
      • 与心臟衰竭POC 和 LOC 设备采用相关的监管和合规问题
  • 市场区隔分析
    • 设备类型：利用 POC 和 LOC 设备作为心臟生物标记分析仪，用于早期发现心臟衰竭病例
    • 技术：人们对基于生物感测器的系统的兴趣日益浓厚，可用于即时测量关键的心臟生物标记
    • 研究类型：采用代谢组学测试监测疾病进展并评估治疗性介入对心臟衰竭的影响
    • 最终用户：居家照护机构越来越多地使用可携式、易于使用的 POC 和 LOC 设备
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社会
    • 技术的
    • 合法的
    • 环境

第六章心臟衰竭POC 和 LOC 设备市场（依测试类型）

  • 基因组检测
  • 代谢组学测试
  • 蛋白质体学检测

第七章心臟衰竭POC 和 LOC 设备市场（以设备类型）

  • 诊断设备
    • 心臟生物标记分析仪
    • 心臟影像影像设备
    • 心电图（ECG）
  • 穿戴式装置
    • 体外心臟去颤器
    • 心率监测器

第 8 章心臟衰竭POC 和 LOC 设备市场（按技术）

  • 基于生物感测器的系统
  • 基于成像和电阻的平台
  • 免疫检测
  • 基于核酸的平台

第九章心臟衰竭POC 和 LOC 设备市场（按最终用户）

  • 辅助生活医疗保健
  • 居家护理设施
  • 医院和诊所
  • 实验室

10. 美洲心臟衰竭POC 和 LOC 设备市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

11. 亚太地区心臟衰竭POC和LOC设备市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

12. 欧洲、中东和非洲地区心臟衰竭POC 和 LOC 设备市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2024年市场占有率分析
  • 2024年FPNV定位矩阵
  • 竞争情境分析
  • 战略分析与建议

公司名单

  • Abbott Laboratories
  • ACON Laboratories Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Boston Scientific Corporation
  • Cipla Limited
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fukuda Denshi Co., Ltd.
  • Jant Pharmacal Corporation
  • Johari Digital India Limited by Syrma SGS
  • Koninklijke Philips NV
  • LifeSign LLC
  • LifeSync
  • Luminex Corporation by DiaSorin SpA
  • Mitsubishi Chemical Group Corporation
  • Nexus Dx, Inc
  • Nihon Kohden Corporation
  • Quidel Corporation
  • Schiller AG
  • Shenzhen EDAN Instrument Co., Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Siemens Healthineers AG
  • Spectral Diagnostics Inc.
  • Trinity Biotech PLC
Product Code: MRR-CA17E905EA91

The Heart Failure POC & LOC Devices Market was valued at USD 267.11 million in 2024 and is projected to grow to USD 301.92 million in 2025, with a CAGR of 13.33%, reaching USD 566.18 million by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 267.11 million
Estimated Year [2025] USD 301.92 million
Forecast Year [2030] USD 566.18 million
CAGR (%) 13.33%

In today's fast-changing healthcare environment, the realm of heart failure point-of-care (POC) and laboratory-on-a-chip (LOC) devices is experiencing a pivotal transformation. Market dynamics are shifting rapidly, driven by technological innovations and increasing clinical demand. This executive summary provides an in-depth exploration of emerging trends, segmented insights, and competitive benchmarks, enabling stakeholders to comprehend the direction of market growth. The integration of sophisticated diagnostic methodologies with streamlined patient management approaches is reshaping traditional paradigms. By deploying innovative testing platforms, sophisticated device architectures, and user-focused design, the market landscape bridges the gap between urgent care and diagnostic precision.

The evolution in this space has been influenced by both critical technological breakthroughs and shifting patient demographics. The significance of these devices lies in their capability to deliver timely and accurate diagnostics, which are essential for reducing heart failure-related events. In an era where rapid decision-making is clinical gold, heart failure POC and LOC devices stand as a testament to the convergence of engineering excellence and medical insight. As adopters of high-performance diagnostic tools pivot towards solutions that offer enhanced reliability and ease of use, the overall trajectory of the industry points to a future where real-time data informs treatment pathways like never before.

This summary aims to outline essential components-including market segmentation, regional influence, strategic insight, and actionable recommendations-for decision-makers looking to harness the potential of these evolving platforms. It provides an articulate narrative that not only reviews current conditions but also projects a future that promises to redefine early diagnosis and ongoing management for heart failure.

Furthermore, the discussion introduces underlying factors such as regulatory evolution, patient safety enhancements, and integration with digital ecosystems. Each element plays a crucial role in setting the stage for widespread market adoption. Building on empirical evidence and comprehensive market research, this narrative is designed to empower both seasoned experts and industry newcomers with a clear roadmap for success.

Transformative Shifts in the Landscape of Heart Failure Diagnostics

The landscape of heart failure diagnostics has undergone transformative changes in recent years, largely driven by innovative technology and dynamic market demand. A marked shift stems from a collective move towards rapid, decentralized, and patient-centric diagnostic solutions. The evolution in technology is not only streamlining workflows but also redefining the roles of traditional medical infrastructures in facilitating early detection and continuous monitoring. The emphasis on real-time data and immediate decision-making has shaped a new narrative where patient outcomes are significantly improved through timely identification of cardiac anomalies.

Healthcare providers are now increasingly integrating advanced diagnostic tools that bring laboratory-level analysis to point-of-care settings. This shift is supported by a strong demand for accuracy, speed, and ease of use. The transition from cumbersome laboratory procedures to compact and efficient LOC devices has been a game-changer. With advancements such as miniaturized platforms and the digitization of diagnostic processes, heart failure management has experienced an evolution that supports not only clinical outcomes but also operational efficiency in healthcare settings.

Furthermore, rapid technological advancements have made it possible to combine multiple testing methodologies into unified diagnostic platforms. This convergence of technologies is paving the way for a holistic approach to patient care, one that encompasses comprehensive biomarker analysis, real-time monitoring, and efficient data management. Industry leaders are now focused on building systems that are scalable, interoperable, and clinically robust. The infusion of digital health platforms with the latest in sensor technology has spurred innovations that are expected to revolutionize disease management protocols in the near future.

Competing solutions are increasingly centered around the philosophy of patient empowerment, making diagnostics accessible outside traditional clinical settings. This democratization of healthcare is anchored in the shift towards portable and user-friendly devices that facilitate continuous care for chronic conditions. The integration of biometric data and actionable insights into wearable devices exemplifies the transformative approach undertaken by market leaders. Consequently, these shifts are not only reshaping how care is delivered but also redefining market boundaries and investment opportunities in the heart failure diagnostic landscape.

Key Segmentation Insights into Heart Failure POC & LOC Devices

A comprehensive understanding of market segmentation is crucial for decoding the nuanced landscape of heart failure POC and LOC devices. Segmentation plays a pivotal role in tailoring diagnostics to address specific clinical needs. An analytical approach to segmentation reveals that the market is methodically divided based on test type, device type, technology, and end user. Each segmentation criterion encapsulates distinct categories, thereby guiding market strategies and development efforts.

In terms of test type, the market is segmented across genomic testing, metabolomic testing, and proteomic testing. Each of these testing types offers a unique perspective on capturing the molecular underpinnings of heart failure, providing clinicians with a robust profile for early diagnosis and effective management strategies. Genomic testing allows for the identification of inherited risk factors, while metabolomic testing provides insight into the biochemical processes underpinning patient health. Proteomic testing, on the other hand, contributes precise information regarding protein dynamics and their relation to cardiac function.

Delving into device type, the segmentation distinguishes between diagnostic devices and wearable devices. Diagnostic devices, comprising cardiac biomarker analyzers, cardiac imaging devices, and electrocardiogram (ECG) systems, bring high-precision laboratory capabilities to the bedside. These instruments are engineered to deliver accurate data expeditiously, thereby facilitating rapid clinical decisions in acute settings. Wearable devices, including external defibrillators and heart rate monitors, represent a shift towards continuous and real-time patient monitoring outside hospital confines. Their role in non-invasive diagnostics complements the more elaborate assessments conducted in controlled environments.

When examining technology, the analysis highlights the prominence of biosensor-based systems, imaging and impedance-based platforms, immunoassays, and nucleic acid-based platforms. These technological innovations ensure a level of sensitivity and specificity that is vital for effective heart failure diagnosis. They leverage advanced materials and microfluidics, provide rapid signal processing, and integrate seamlessly with digital health records for enhanced data analytics.

Finally, the segmentation by end user addresses varied clinical environments ranging from assisted living healthcare and home care facilities to hospitals & clinics and specialized laboratories. This broad spectrum illustrates how market offerings are diversified to meet the varying operational requirements and technological capacities of different care settings. The flexibility of these devices to adapt to diverse end user environments amplifies their relevance and aids in widespread market penetration.

Each segmentation layer not only defines the technical and functional parameters of these devices but also aligns developmental priorities with prevailing patient and healthcare professional needs. Understanding these critical segmentation insights provides clarity on the mechanisms driving the innovation and deployment of heart failure diagnostic solutions.

Based on Test Type, market is studied across Genomic Testing, Metabolomic Testing, and Proteomic Testing.

Based on Device Type, market is studied across Diagnostic Devices and Wearable Devices. The Diagnostic Devices is further studied across Cardiac Biomarker Analyzers, Cardiac Imaging Devices, and Electrocardiogram (ECG). The Wearable Devices is further studied across External Defibrillator and Heart Rate Monitors.

Based on Technology, market is studied across Biosensor-based systems, Imaging & impedance-based platforms, Immunoassays, and Nucleic acid-based platforms.

Based on End User, market is studied across Assisted Living Healthcare, Home Care Facilities, Hospitals & Clinics, and Laboratory.

Key Regional Insights in the Global Heart Failure Device Market

The global market for heart failure POC and LOC devices exhibits distinct regional dynamics, reflecting a diverse landscape that is influenced by varying regulatory, economic, and demographic factors. Comprehensive regional insights are derived by evaluating market trends in the Americas, in Europe, Middle East & Africa, and in Asia-Pacific. Each region presents unique challenges and opportunities, driving both the adoption of advanced technologies and the evolution of patient care practices.

In the Americas, the market benefits from advanced healthcare infrastructure, robust R&D investments, and a high adoption rate of new technologies. This region is characterized by a strong tradition of innovation in medical devices, where consumer demands and healthcare excellence converge to propel the evolution of heart failure diagnostics. The convergence of policy support, investment in digital health, and shifting demographics make the Americas a key driver for global market expansion.

Europe, Middle East & Africa provides a varied landscape marked by a blend of established healthcare systems and emerging market dynamics. This region is notable for its rigorous regulatory standards and a diversified patient population that demands specialized diagnostics. Market players in this area are focusing on interoperability and integration of data analytics with traditional healthcare services, striving to maintain the balance between cutting-edge technology usage and cost-effectiveness. The region represents a fertile ground for innovations that support chronic disease management and patient monitoring, spearheading a move towards harmonized standards and collaborative healthcare initiatives.

Asia-Pacific stands out as a rapidly evolving market with significant growth potential driven by large patient populations and increasing healthcare investments. There is a strong momentum towards adopting advanced diagnostic tools, where local innovation meets global technological trends. With rising per capita incomes and escalating health awareness, the demand for POC and LOC devices in the heart failure domain is accelerating. This region is also witnessing remarkable collaborations between technological firms and healthcare institutions, further fueling industry growth through localized adaptation of global healthcare standards.

The regional analysis underscores the importance of targeted strategies that cater to the unique healthcare demands in different markets. The dynamic interplay of economic, regulatory, and ethnographic elements across these regions not only shapes the competitive landscape but also dictates the pace at which innovations are integrated into clinical practice. By comprehensively exploring these regional nuances, stakeholders gain the ability to navigate a multifaceted market environment, ensuring that diagnostic solutions are both effective and regionally tailored.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Insights in the Heart Failure Diagnostic Space

The competitive landscape of heart failure POC and LOC devices is marked by contributions from a range of established and emerging players whose collective efforts have significantly advanced diagnostic technology. Major companies are leveraging their deep industry experience, research capabilities, and innovative product pipelines to address the growing demand for rapid and reliable heart failure diagnostic platforms. Notable companies include Abbott Laboratories, ACON Laboratories Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Boston Scientific Corporation, Cipla Limited, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fukuda Denshi Co., Ltd., Jant Pharmacal Corporation, Johari Digital India Limited by Syrma SGS, Koninklijke Philips N.V., LifeSign LLC, LifeSync, Luminex Corporation by DiaSorin S.p.A., Mitsubishi Chemical Group Corporation, Nexus Dx, Inc, Nihon Kohden Corporation, Quidel Corporation, Schiller AG, Shenzhen EDAN Instrument Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Spectral Diagnostics Inc., and Trinity Biotech PLC. Each of these companies underscores different strategic priorities such as technological advancement, market expansion, and strategic partnerships.

Market frontrunners are pushing the envelope by focusing on integrating biosensor technology with miniaturized platforms capable of delivering laboratory-quality results at the point-of-care. Their R&D efforts are supplemented by strategic investments aimed at incorporating digital health and advanced data-processing capabilities into new devices. This approach not only improves diagnostic efficiency but also enhances patient outcome tracking, crucial for long-term disease management. These companies are continuously exploring avenues to reduce device turnaround times while maintaining clinical accuracy, positioning themselves as key drivers in the transformation of heart failure diagnostics.

In addition to technological innovations, many industry leaders are also concentrating on expanding their geographic footprint, ensuring that breakthrough diagnostic solutions reach more diverse patient populations. The robust product pipelines of these companies, combined with significant financial investments in next-generation diagnostic tools, are setting new industry standards. Their current initiatives include refining testing platforms to cater to specific clinical settings and maximizing output through device modularity and enhanced interoperability. Competitive dynamics are further enriched by strategic mergers, partnerships, and acquisitions, which are streamlining operations and reducing time-to-market for innovative diagnostics.

Overall, the market insights from leading companies reflect a concerted effort to overcome longstanding challenges in heart failure management. Their combined influence continues to elevate industry benchmarks, encouraging both incremental improvements and radical innovations. This interplay of competition and collaboration fosters an environment ripe for breakthrough developments, where technological superiority and responsive patient care coalesce into a new era for heart failure diagnostics.

The report delves into recent significant developments in the Heart Failure POC & LOC Devices Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ACON Laboratories Inc., Becton, Dickinson and Company, Bio-Rad Laboratories, Inc., bioMerieux S.A., Boston Scientific Corporation, Cipla Limited, Danaher Corporation, F. Hoffmann-La Roche Ltd., Fukuda Denshi Co., Ltd., Jant Pharmacal Corporation, Johari Digital India Limited by Syrma SGS, Koninklijke Philips N.V., LifeSign LLC, LifeSync, Luminex Corporation by DiaSorin S.p.A., Mitsubishi Chemical Group Corporation, Nexus Dx, Inc, Nihon Kohden Corporation, Quidel Corporation, Schiller AG, Shenzhen EDAN Instrument Co., Ltd., Shenzhen Mindray Bio-Medical Electronics Co., Ltd., Siemens Healthineers AG, Spectral Diagnostics Inc., and Trinity Biotech PLC. Actionable Recommendations for Industry Leaders in Heart Failure Diagnostics

For industry leaders seeking to navigate the competitive arena of heart failure POC and LOC devices, several strategic recommendations emerge from a deep analysis of market dynamics, technological advancements, and evolving patient needs. To remain at the forefront of this rapidly changing landscape, companies should focus on establishing a robust innovation pipeline, embracing cross-disciplinary research, and leveraging data-driven insights to direct product development.

A key recommendation is to increase investments in R&D, with a focus on the integration of biosensor technology and advanced computational platforms. By fostering innovation in this space, companies can anticipate the next generation of diagnostic tools that merge rapid analysis with user-friendly interfaces. Scaling the pace of innovation is critical to meeting the dynamic demands of a market that is increasingly inclined towards personalized and decentralized care. In addition, collaboration with academic institutions and technology startups can infuse fresh perspectives that stimulate disruptive innovation in diagnostic methodologies.

Furthermore, it is essential to adopt a patient-centric approach in developing diagnostic instruments. Industry leaders must prioritize features such as portability, ease of use, and real-time data integration to enhance user engagement across varied clinical and non-clinical settings. Strategic partnerships with digital health platforms and telemedicine providers can also extend the reach of these diagnostic devices, thereby encompassing a broader user base. By aligning product development with holistic patient care strategies, companies can solidify their market position and drive favorable patient outcomes.

A strategic focus on emerging markets and regional diversity is another recommended pathway. By tailoring diagnostic solutions to meet specific regional needs-whether in the Americas, Europe, Middle East & Africa, or Asia-Pacific-companies can leverage local opportunities and comply with region-specific regulatory requirements. This regional customization not only bolsters market penetration but also builds brand credibility among diverse healthcare providers.

Lastly, proactive engagement in shaping regulatory policies is advised. As advancements in diagnostic technologies continue to outpace conventional regulatory frameworks, early dialogue with policy makers can help secure necessary certifications and streamline market entry. By maintaining open lines of communication with regulatory authorities, industry leaders can preemptively address potential compliance challenges, thereby ensuring a smoother innovation-to-market transition.

These actionable recommendations, when executed strategically, empower companies to navigate uncertainties, harness emerging opportunities, and ultimately set a new standard for excellence in heart failure diagnostic care.

Conclusion: The Future of Heart Failure POC & LOC Diagnostics

In conclusion, the heart failure diagnostic market is undergoing significant yet promising transformation, driven by an amalgamation of rapid technological advancements, innovative segmentation strategies, and aggressive market expansion. The convergence of molecular testing approaches, device diversification, and cross-functional technologies has culminated in the creation of devices that bridge the gap between speedy diagnostics and comprehensive patient care.

The insights provided throughout this analysis reinforce the potential of POC and LOC devices to dramatically reshape clinical pathways for heart failure management. Continuous innovation, meticulous market segmentation, and tailored regional strategies serve as cornerstones for advancing diagnostic precision while ensuring improved patient outcomes. Moreover, the competitive landscape is enriched by leading companies that are fervently investing in next-generation diagnostics, underscoring the dynamic nature of this industry.

This narrative has established a clear link between advanced diagnostic methodologies and the future trajectory of heart failure management. The strategic integration of genomic, metabolomic, and proteomic tests, combined with both advanced diagnostic and wearable device technologies, heralds a new era in personalized medicine. As market players continue to invest in R&D and foster strategic alliances, the future of heart failure diagnostics looks increasingly robust and patient-centric.

The insights drawn from advanced technology and innovative data integration promise to not only reduce diagnostic delays but also empower clinicians with actionable, real-time information. This evolution is poised to transform clinical decision-making processes and ensure that diagnostic tools are in lockstep with the evolving complexities of cardiac care. Ultimately, the success of these initiatives will depend on sustained innovation, thorough market understanding, and the ability to adapt to regional and global healthcare trends.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing prevalence and incidence of heart failure globally enhancing need for timely diagnosis and management device
      • 5.1.1.2. Rising need for cost-effective and accessible LOC device in cardiac biomarker analyse
    • 5.1.2. Restraints
      • 5.1.2.1. Rising concern associated with product recall of heart failure POC & LOC devices
    • 5.1.3. Opportunities
      • 5.1.3.1. Integration of digital health platforms and telemedicine solutions in POC & LOC devices to enable remote patient monitoring
      • 5.1.3.2. Increasing collaborations between technology firms and healthcare providers for development of heart failure POC & LOC devices
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory and compliance issue associated with adoptions of heart failure POC & LOC devices
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Device Type: Utilizating POC & LOC devices as cardiac biomarker analyzers for early detection in heart failure cases
    • 5.2.2. Technology: Rising preference for biosensor-based systems for real-time measurements of vital cardiac biomarkers
    • 5.2.3. Test Type: Adoption of metabolomic testing for monitoring disease progression and assessing impact of therapeutic interventions in heart failure
    • 5.2.4. End User: Increasing utilization of portable and user-friendly POC and LOC devices for home care facilities
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Heart Failure POC & LOC Devices Market, by Test Type

  • 6.1. Introduction
  • 6.2. Genomic Testing
  • 6.3. Metabolomic Testing
  • 6.4. Proteomic Testing

7. Heart Failure POC & LOC Devices Market, by Device Type

  • 7.1. Introduction
  • 7.2. Diagnostic Devices
    • 7.2.1. Cardiac Biomarker Analyzers
    • 7.2.2. Cardiac Imaging Devices
    • 7.2.3. Electrocardiogram (ECG)
  • 7.3. Wearable Devices
    • 7.3.1. External Defibrillator
    • 7.3.2. Heart Rate Monitors

8. Heart Failure POC & LOC Devices Market, by Technology

  • 8.1. Introduction
  • 8.2. Biosensor-based systems
  • 8.3. Imaging & impedance-based platforms
  • 8.4. Immunoassays
  • 8.5. Nucleic acid-based platforms

9. Heart Failure POC & LOC Devices Market, by End User

  • 9.1. Introduction
  • 9.2. Assisted Living Healthcare
  • 9.3. Home Care Facilities
  • 9.4. Hospitals & Clinics
  • 9.5. Laboratory

10. Americas Heart Failure POC & LOC Devices Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Heart Failure POC & LOC Devices Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Heart Failure POC & LOC Devices Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Asda and PocDoc partner to expand access to heart health diagnostics
    • 13.3.2. AliveCor launches innovative point-of-care ECG tech in Europe
    • 13.3.3. Roche Diagnostics India launches NT-proBNP test for early detection of heart failure
    • 13.3.4. Polymedco secures FDA clearance for rapid PATHFAST hs-cTnI-II troponin test
    • 13.3.5. ACON Laboratories expands POC testing with On Call MultiPro launch
    • 13.3.6. Jana Care and Roche collaborate to develop at-home blood testing
    • 13.3.7. Cipla unveils Cippoint, a rapid point-of-care diagnostic device
  • 13.4. Strategy Analysis & Recommendation
    • 13.4.1. F. Hoffmann-La Roche Ltd
    • 13.4.2. Siemens Healthineers AG
    • 13.4.3. Koninklijke Philips N.V.
    • 13.4.4. Danaher Corporation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. ACON Laboratories Inc.
  • 3. Becton, Dickinson and Company
  • 4. Bio-Rad Laboratories, Inc.
  • 5. bioMerieux S.A.
  • 6. Boston Scientific Corporation
  • 7. Cipla Limited
  • 8. Danaher Corporation
  • 9. F. Hoffmann-La Roche Ltd.
  • 10. Fukuda Denshi Co., Ltd.
  • 11. Jant Pharmacal Corporation
  • 12. Johari Digital India Limited by Syrma SGS
  • 13. Koninklijke Philips N.V.
  • 14. LifeSign LLC
  • 15. LifeSync
  • 16. Luminex Corporation by DiaSorin S.p.A.
  • 17. Mitsubishi Chemical Group Corporation
  • 18. Nexus Dx, Inc
  • 19. Nihon Kohden Corporation
  • 20. Quidel Corporation
  • 21. Schiller AG
  • 22. Shenzhen EDAN Instrument Co., Ltd.
  • 23. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 24. Siemens Healthineers AG
  • 25. Spectral Diagnostics Inc.
  • 26. Trinity Biotech PLC

LIST OF FIGURES

  • FIGURE 1. HEART FAILURE POC & LOC DEVICES MARKET MULTI-CURRENCY
  • FIGURE 2. HEART FAILURE POC & LOC DEVICES MARKET MULTI-LANGUAGE
  • FIGURE 3. HEART FAILURE POC & LOC DEVICES MARKET RESEARCH PROCESS
  • FIGURE 4. HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2030 (USD THOUSAND)
  • FIGURE 6. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 16. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 17. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 18. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 19. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 20. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 21. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD THOUSAND)
  • FIGURE 24. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 25. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. HEART FAILURE POC & LOC DEVICES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, 2018-2030 (USD THOUSAND)
  • TABLE 4. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 5. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 6. HEART FAILURE POC & LOC DEVICES MARKET DYNAMICS
  • TABLE 7. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 8. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY GENOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 9. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY METABOLOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 10. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY PROTEOMIC TESTING, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 11. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 12. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 13. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC BIOMARKER ANALYZERS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 14. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY CARDIAC IMAGING DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 15. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ELECTROCARDIOGRAM (ECG), BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 16. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 17. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 18. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY EXTERNAL DEFIBRILLATOR, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 19. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HEART RATE MONITORS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 20. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 21. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 22. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY BIOSENSOR-BASED SYSTEMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 23. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMAGING & IMPEDANCE-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 24. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 25. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY NUCLEIC ACID-BASED PLATFORMS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 26. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 27. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY ASSISTED LIVING HEALTHCARE, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 28. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOME CARE FACILITIES, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 29. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 30. GLOBAL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY LABORATORY, BY REGION, 2018-2030 (USD THOUSAND)
  • TABLE 31. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 32. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 33. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 34. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 35. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 36. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 37. AMERICAS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 38. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 39. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 40. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 41. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 42. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 43. ARGENTINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 44. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 45. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 46. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 47. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 48. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 49. BRAZIL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 50. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 51. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 52. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 53. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 54. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 55. CANADA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 56. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 57. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 58. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 59. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 60. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 61. MEXICO HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 62. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 63. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 64. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 65. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 66. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 67. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 68. UNITED STATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY STATE, 2018-2030 (USD THOUSAND)
  • TABLE 69. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 70. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 71. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 72. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 73. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 74. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 75. ASIA-PACIFIC HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 76. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 77. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 78. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 79. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 80. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 81. AUSTRALIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 82. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 83. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 84. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 85. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 86. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 87. CHINA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 88. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 89. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 90. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 91. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 92. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 93. INDIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 94. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 95. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 96. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 97. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 98. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 99. INDONESIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 100. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 101. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 102. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 103. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 104. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 105. JAPAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 106. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 107. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 108. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 109. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 110. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 111. MALAYSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 112. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 113. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 114. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 115. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 116. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 117. PHILIPPINES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 118. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 119. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 120. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 121. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 122. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 123. SINGAPORE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 124. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 125. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 126. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 127. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 128. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 129. SOUTH KOREA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 130. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 131. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 132. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 133. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 134. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 135. TAIWAN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 136. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 137. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 138. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 139. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 140. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 141. THAILAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 142. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 143. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 144. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 145. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 146. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 147. VIETNAM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY COUNTRY, 2018-2030 (USD THOUSAND)
  • TABLE 155. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 156. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 157. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 158. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 159. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 160. DENMARK HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 161. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 162. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 163. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 164. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 165. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 166. EGYPT HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 167. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 168. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 169. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 170. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 171. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 172. FINLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 173. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 174. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 175. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 176. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 177. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 178. FRANCE HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 179. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 180. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 181. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 182. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 183. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 184. GERMANY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 185. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 186. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 187. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 188. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 189. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 190. ISRAEL HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 191. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 192. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 193. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 194. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 195. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 196. ITALY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 197. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 198. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 199. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 200. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 201. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 202. NETHERLANDS HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 203. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 204. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 205. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 206. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 207. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 208. NIGERIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 209. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 210. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 211. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 212. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 213. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 214. NORWAY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 215. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 216. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 217. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 218. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 219. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 220. POLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 221. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 222. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 223. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 224. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 225. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 226. QATAR HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 227. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 228. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 229. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 230. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 231. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 232. RUSSIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 233. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 234. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 235. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 236. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 237. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 238. SAUDI ARABIA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 239. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 240. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 241. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 242. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 243. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 244. SOUTH AFRICA HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 245. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 246. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 247. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 248. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 249. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 250. SPAIN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 251. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 252. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 253. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 254. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 255. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 256. SWEDEN HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 257. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 258. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 259. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 260. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 261. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 262. SWITZERLAND HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 263. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 264. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 265. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 266. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 267. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 268. TURKEY HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 269. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 270. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 271. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 272. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 273. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 274. UNITED ARAB EMIRATES HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 275. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TEST TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 276. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DEVICE TYPE, 2018-2030 (USD THOUSAND)
  • TABLE 277. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY DIAGNOSTIC DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 278. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY WEARABLE DEVICES, 2018-2030 (USD THOUSAND)
  • TABLE 279. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD THOUSAND)
  • TABLE 280. UNITED KINGDOM HEART FAILURE POC & LOC DEVICES MARKET SIZE, BY END USER, 2018-2030 (USD THOUSAND)
  • TABLE 281. HEART FAILURE POC & LOC DEVICES MARKET SHARE, BY KEY PLAYER, 2024
  • TABLE 282. HEART FAILURE POC & LOC DEVICES MARKET, FPNV POSITIONING MATRIX, 2024